This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CombiMatrix Provides Update On Financial Results And Strategic Restructuring -- Appoints Judd Jessup As Full-Time CEO

IRVINE, Calif., Aug. 16, 2010 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) today reported financial results for the three month period ended June 30, 2010 and provided operational updates on its strategic restructuring plan.  Key highlights for the second quarter and through the date of this release include:

  • 51% increase in diagnostic lab revenues from Q2-2009 to Q2-2010
  • 12% sequential increase in diagnostic lab revenues from Q1-2010 to Q2-2010
  • Shut-down of CustomArray business substantially complete; revised estimate of total cash restructuring costs reduced to $975,000 - significantly below initial estimates of $1.5 million.
  • Relocation to Irvine, California completed in early August, approximately one month ahead of schedule.
  • Recognized one-time, non-cash impairment charges of approximately $20.3 million; ended June 30, 2010 with $10.2 million in cash.

"The first stage of our strategic restructuring plan is in its final phase and is running ahead of schedule and below budget," stated Mark McGowan, Chairman and Chief Executive Officer of CombiMatrix. "With phase one of our restructuring drawing to a close, the next step in our plan was to hire a highly qualified, commercially oriented CEO and focus company efforts intensely on our Molecular Diagnostics business. After working through an extensive process in conjunction with Caldwell Partners, involving multiple rounds of vetting and drawing from a large number of highly qualified candidates, CBMX is delighted to have retained Judd Jessup, former CEO of US LABS, as our permanent CEO, effective August 23, 2010. Mr. Jessup has extensive experience within the healthcare and managed care industries, and a proven track record with turnaround situations analogous to present-day CombiMatrix. He is the ideal candidate for the job ahead," concluded Mr. McGowan. 

"I am excited about the opportunity ahead of us at CombiMatrix," noted Judd Jessup.  "I appreciate the 'heavy lifting' which has already been accomplished during the restructuring and look forward to focusing on continuing to build a high performance laboratory," concluded Mr. Jessup.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
CBMX $1.77 0.00%
AAPL $128.95 0.00%
FB $78.99 0.00%
GOOG $537.90 0.00%
TSLA $226.03 0.00%

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs